Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000113104 | SCV000300568 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Ambry Genetics | RCV002433599 | SCV002751765 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-08-24 | criteria provided, single submitter | clinical testing | The c.2842dupG pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a duplication of G at nucleotide position 2842, causing a translational frameshift with a predicted alternate stop codon (p.V948Gfs*11). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV004998231 | SCV005624370 | pathogenic | not provided | 2023-12-21 | criteria provided, single submitter | clinical testing | The BRCA2 c.2842dup (p.Val948Glyfs*11) variant alters the translational reading frame of the BRCA2 mRNA and causes the premature termination of BRCA2 protein synthesis. This variant has been reported in the published literature in an individual with contralateral invasive breast cancer (PMID: 36091166 (2022)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. |
Breast Cancer Information Core |
RCV000113104 | SCV000146129 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2003-12-23 | no assertion criteria provided | clinical testing |